Pre-Seed Biotech Fundraising With No Clinical Data: How to Raise Before You Have Proof

Every pre-seed biotech founder runs into the same wall. Investors want to see that the science works. But generating the data that proves the science works costs money, money you are trying to raise. You need capital to produce results, and you are being told you need results to attract capital. It is the defining catch-22 of the earliest stage, and it stops a lot of good founders before they start.

Here is the reframe that gets you past it. At pre-seed, you are not selling data. You cannot, because you do not have any yet, and the investors who fund this stage know that. The traditional biotech path assumed a founder would develop preliminary results and only then take that data to venture capitalists, but as Nature Biotechnology has noted, that playbook increasingly leaves out the many founders tackling ambitious, capital-intensive science who do not yet fit those criteria.

The founders who raise pre-seed successfully are not the ones with the most data. They are the ones who understand what actually gets funded before there is proof: a credible team, a rigorous scientific hypothesis, defensible IP, external validation, and a precise plan for the first data point, pitched to the specific investors whose entire thesis is backing science before it is de-risked.

You are not too early. You are pitching the wrong story to the wrong people. This guide: Pre-Seed Biotech Fundraising With No Clinical Data fixes both.

What Pre-Seed Biotech Fundraising Actually Is in 2026

Pre-seed is the capital that takes a scientific hypothesis to its first meaningful proof point. It is not a smaller version of a seed round. It is a different proposition with a different bar, a different investor base, and a different definition of what “ready” means.

The distinction matters because the two stages evaluate you on different evidence. Seed-stage investors expect demonstrable progress toward commercialization and want to see that the technology works outside a controlled setting.

Pre-seed investors are betting on the founding team and the scientific promise before that proof exists. Treating the two as interchangeable is the fastest way to mis-target your raise and burn months pitching people who were never going to move.

The market makes that targeting discipline more important than it was two years ago. Early-stage biotech financings are on track for their worst year since before the pandemic, with first-time rounds heading toward their lowest count this decade as investors continue to concentrate capital in later-stage companies.

The capital still exists, but it is more selective. That selectivity rewards founders who know exactly who funds pre-data science and approach only them, and it punishes founders who spray a generic deck across every biotech investor they can find.

The Honest Truth: Some Investors Will Not Engage Pre-Data, and That Is Fine

Here is the part most guides skip. A large share of biotech capital genuinely will not look at you before you have data, and in a market that is visibly favoring later-stage companies, that share is not shrinking. Pitching those funds with no data is not persistence. It is a waste of your runway and theirs.

The skill at pre-seed is not convincing data-stage investors to lower their bar. It is identifying the specific subset of funders whose mandate is to back you now, and concentrating your energy there. Targeting is half the battle, and getting it wrong is the most common way pre-data founders lose a year.

The Good News: Pre-Seed Investors Are Not Looking for Clinical Data

The investors who fund this stage are not waiting for a dataset. They are evaluating whether your science is worth believing before the data exists, and they are equipped to make that judgment.

This is possible because the people making these decisions can often evaluate the science directly. Many early-stage biotech funds are led by PhDs, MDs, and former operators who assess the underlying biology themselves rather than waiting for a result to do the convincing.

When you pitch a pre-seed biotech investor, you are frequently pitching someone with the scientific training to be persuaded by mechanism, rationale, and experimental design. That is an advantage for a scientist-founder, not a disadvantage. Your job is not to fake proof you do not have. It is to make the case for why the proof, when it comes, will confirm what you already understand about the biology.

Even without results, investors are looking for evidence that you have reduced some of the risk. De-risking pre-data means removing doubt on every dimension you can control: a team that can clearly execute, a hypothesis that holds up to scientific scrutiny, IP that creates a real barrier, external validation that signals others believe in the work, and a plan whose first milestone is concrete and achievable with the money you are asking for. You cannot de-risk the biology yet. That is what the round is for. You can de-risk everything around it.

What Pre-Seed Biotech Investors Actually Evaluate Instead

When there is no clinical data in the room, five things carry the weight. Treat these as the spine of your raise, your deck, and every investor conversation.

1. Founding Team Quality and Domain Pedigree

At pre-seed, the team is the investment. Investors expect a strong, well-balanced founding team that can execute, and PhDs, MDs, former biotech executives, and recognized domain experts carry real weight, because at this stage your credibility is the proxy for your eventual data.

Make the team the front of your story: who you are, why you specifically are equipped to solve this problem, what you have published or built before, and which gaps you have filled with co-founders, advisors, or named early hires.

A balanced team signals that you can run a company, not just a lab. Pair deep scientific founders with someone who carries operational or commercial judgment, even part-time, and you remove a category of execution risk that solo scientist-founders leave wide open. Investors are not only asking whether the science is right. They are asking whether this group is the one that can turn it into a company.

2. Scientific Hypothesis Clarity and Differentiation

You may not have results, but you must have a rigorous, defensible explanation of why this will work. Expect investors to probe the mechanism hard: why does this approach work, what is the biological basis, why has it not been done before, and why will the data, when it exists, confirm it.

A clear, well-reasoned mechanistic argument, grounded in the published literature and your own prior work, can carry enormous weight with a scientifically trained investor.

Differentiation is the other half. It is not enough to be working on a large problem. You have to explain precisely what current approaches get wrong, why they fail the patient population you are targeting, and why your approach is meaningfully different rather than incrementally better. Tie that science directly to a large, unmet clinical need and to who ultimately pays for the solution.

At this stage, a specific, patient-level account of the need is more credible than a sweeping market-size claim. Founders building AI-enabled or computation-led platforms face a particular version of this challenge, because the story is easy to overstate and hard to make legible, so be deliberate about how you frame that edge for investors and disciplined about separating what the platform has shown from what it promises.

3. Intellectual Property Position

In the absence of data, IP becomes the most concrete asset you can point to. In the preclinical stage, biotech companies are valued largely on the strength of their intellectual property, and secured patents or exclusive licenses measurably increase investor confidence. Your IP needs to create a real barrier to entry: patents, licenses, or proprietary technology that competitors cannot easily route around.

If your science came out of a university, your licensing position is part of the story, and investors will want to know you actually control the rights to what you are building on.

A provisional patent application is inexpensive and fast to prepare with a qualified attorney, and it establishes your priority date while giving you a year to file the full application. There is no good reason to walk into an investor meeting without that step done.

4. Non-Dilutive Validation: Grants as Peer-Reviewed Credibility

A federal grant or foundation award does something a pitch deck cannot. It tells an investor that an independent panel of scientific reviewers evaluated your hypothesis and chose to fund it.

At a stage when you have no clinical data, that third-party, peer-reviewed validation is one of the strongest credibility signals available to you, and it is one you can pursue before you raise a dollar of equity.

Non-dilutive funding is important enough at pre-seed that it deserves its own treatment, which is the next section. For now, understand that investors read a secured SBIR or NIH award as evidence that your science survived outside scrutiny, and that the absence of any non-dilutive strategy reads as a founder who has not done the work.

5. Scientific Advisory Board and KOL Relationships

A credible scientific advisory board converts a founder’s hypothesis into a peer-endorsed scientific program. Named advisors who are respected in your disease area or target mechanism tell an investor that people with reputations to protect have looked at your science and chosen to attach their name to it.

The key is specificity. A long list of vaguely affiliated names is worth less than two genuinely engaged advisors with a defined role in designing and interpreting your early experimental program. Recruit deliberately, give each advisor a real ask, and be ready to explain why each one was chosen.

Key opinion leader relationships work the same way: a clinician or researcher who is willing to speak to the importance of your approach is a validation asset, not a formality.

Why Non-Dilutive Funding Is Your Most Powerful Pre-Seed Credibility Tool

The strategic value of non-dilutive funding at pre-seed extends well beyond the capital. Founders who treat grants purely as a funding source are leaving significant credibility on the table.

Start with the part that is easy to miss. The grant application process itself is a forcing function. Writing a competitive SBIR or STTR proposal requires you to articulate your scientific hypothesis, your regulatory pathway, your competitive landscape, and your specific aims with a precision that most founders never reach on their own.

Many founders find that the proposal is what finally sharpened their thinking, and that every subsequent investor conversation became more efficient because of it. You are not just applying for money. You are building the rigorous narrative that the rest of your raise depends on.

The scale of the opportunity is real. Through the SBIR and STTR programs, known collectively as America’s Seed Fund, coordinated by the Small Business Administration across 11 federal agencies, the federal government awards billions of dollars a year in non-dilutive funding to move technology toward commercialization.

Every award keeps your equity intact, which changes the math of an early raise: capital that costs you no ownership is the cheapest money you will ever take.

One critical update every founder should know. The programs’ authorization lapsed on September 30, 2025, pausing new awards, before Congress reauthorized SBIR and STTR through 2031 in the Small Business Innovation and Economic Security Act, which President Trump signed into law in April 2026 alongside structural reforms, including a new “Strategic Breakthrough” award category and enhanced national-security screening of applicants.

With the programs restarting, agencies are updating their solicitation schedules, so verify current deadlines directly before you plan around them.

Within that system, two agencies matter most for early biotech.

The NIH is the single largest source of non-dilutive capital for health-tech startups. It directs well over $1 billion a year to small businesses, with Phase I awards of roughly $300,000 for six to twelve months of feasibility work, Phase II awards up to about $2 million over two years, and standard application deadlines on January 5, April 5, and September 5.

The detail that matters most for the earliest-stage founder: NIH Phase I generally does not require preliminary data, which means you can apply at the hypothesis stage, before the preclinical package a seed round would demand.

The NSF is the second lane, and it is underused by biotech founders. The NSF SBIR/STTR program provides up to $305,000 for a Phase I award and up to $1.25 million for Phase II over two years, and it funds deep technology across engineering, computing, and the physical sciences with no requirement that the work address a biomedical need.

For AI-enabled biotech platforms, computational biology approaches, and novel research tools, NSF is often a faster and more natural fit than NIH, and it has a track record of funding companies that spun directly out of academic labs.

Beyond SBIR and STTR, the broader non-dilutive landscape is wide. NIH R21 exploratory grants, Department of Defense CDMRP topic-area funding, National Cancer Institute programs, and disease-focused foundation grants from organizations like the Michael J. Fox Foundation, the Cystic Fibrosis Foundation, and JDRF all fund early science in their areas.

Each award, regardless of source, creates a permanent, peer-reviewed credibility signal that compounds in every investor interaction.

Then use what you win. A grant award is only half its value if you let it sit quietly in your records. Put it to work in your outreach:

• Reference recent awards in your pitch emails as third-party validation, not as a footnote.
• Feature awards prominently in the traction or validation section of your deck.
• Frame each award in your founder content around what it funds and which milestone it will generate.
• Add awards to your quarterly investor update with context about what they unlock next.

Who the Right Pre-Seed Investors Actually Are for Biotech

One of the most costly mistakes pre-seed biotech founders make is targeting the wrong investor type, approaching growth-stage funds, crossover investors, or Series B-focused VCs with a pre-clinical company. Misfit targeting wastes months and burns relationship capital with investors who might have been relevant in a later round.

The right pre-seed landscape is wider and more specialized than most first-time founders realize.

Specialist biotech VCs and company-creation firms. Specialist firms move earlier and stay longer than generalist crossover funds. The most active company-creation investors, the Atlas Ventures, ARCH Venture Partners, Third Rock Ventures, and Flagship Pioneerings of the world, are built to fund science before it is de-risked, often with partners who operate as working scientists and run portfolio companies through early milestones themselves.

These firms are competitive and relationship-gated, and a warm referral from a respected academic contact opens far more first meetings than a cold deck ever will. The practical move, as Atlas Venture’s Bruce Booth advises, is to build a list of every biotech VC you can name and filter it by focus area, stage, business model, and geography, then work only the firms whose thesis genuinely fits a pre-data company.

For a systematic approach to building and screening that list, see How to Find and Qualify Investors for a Biotech or Healthcare Startup.

Specialist accelerators. For genuinely pre-data biotech, accelerators are often the most realistic first institutional money, because they are built for exactly this moment. SOSV’s IndieBio writes pre-seed checks of up to roughly $550,000, is almost always the first VC investor in a company, targets around 10% ownership by the seed round, and runs an intensive four-to-five-month program with wet-lab access, reserving the majority of its fund for follow-on rounds.

Programs like Y Combinator’s bio track, Johnson & Johnson’s JLABS, which takes no equity, and the Illumina Accelerator offer their own mixes of capital, lab space, and mentorship. The value is not only the check. It is the validation, the wet-lab infrastructure to generate your first data, and the warm path into the next round.

Pre-seed life-science funds and domain-expert angels. A growing set of specialist funds write first institutional checks at the idea stage. Some write first checks of roughly $500K to $5M at the earliest stages for science-first founders applying compute to chemistry and biology. Alongside them, angels with life-science backgrounds, former pharma executives, biotech operators, and physician-investors, are a major source of pre-seed capital.

They evaluate teams and hypotheses with domain-specific rigor, and they often bring more than money: regulatory connections, clinical network access, and operational mentorship that is directly useful at the earliest stage. Their participation is itself a credibility signal to the institutional investors who come next.

Academic incubators and technology-transfer spinout vehicles. Many major research universities operate seed funds designed to co-invest alongside academic founders spinning out of their labs. For a first-time founder with a strong institutional pedigree, these vehicles are frequently the most accessible path to first capital, and they come with lab infrastructure and university networks attached.

Corporate venture arms at their earliest entry point. The venture arms of large pharmaceutical companies participate in early rounds when the science aligns with their therapeutic priorities. Investors like these bring strategic value that pure financial backers cannot: pipeline visibility, clinical network access, and potential partnership pathways. They are worth mapping where your mechanism fits a specific company’s stated areas of interest.

Disease-focused foundations and patient-advocacy investment vehicles. Organizations such as the Cystic Fibrosis Foundation, JDRF, and the Michael J. Fox Foundation operate investment arms that fund early-stage programs in their disease areas. They bring patient-community relationships and disease-area expertise that is uniquely valuable at pre-seed, and their backing carries a credibility no generalist check can match.

Friends, family, and founder capital, used wisely. At the very earliest point, founders frequently contribute personal capital and raise from friends, family, and angels while applying to accelerators and grant programs. This money is fast and relationship-based, but treat it with discipline: use clean instruments such as a standard SAFE, set clear expectations about the risk, and deploy it specifically to reach the first milestone that unlocks accelerator, grant, or institutional money. The goal of every early dollar is to buy the proof point that makes the next dollar cheaper.

Founder Visibility: The Credibility Investors Find Before You Pitch

When there is no dataset to do the talking, the founder’s visible credibility carries disproportionate weight. An investor doing diligence on a pre-data company is, in large part, doing diligence on you, and what they find when they look you up shapes their confidence before the first meeting ever happens.

This is not vanity. It is a substitute for the proof you do not yet have. A founder who is findable and credible when an investor searches their name gives that investor evidence of expertise and judgment that no early-stage data room can.

The most effective way to build that evidence is to publish substantive perspective on your field, sharing genuine scientific thinking rather than promotional noise. Done consistently, it puts your work on investors’ radar and warms the path long before you ask for a meeting, so that by the time you reach out, you are a name they already recognize and respect.

How to Build a Pre-Seed Investor Narrative Without Clinical Data

The pre-seed investor narrative is not built around data. It is built around reasoning. The hypothesis-to-milestone structure is what makes it work, and it follows four steps.

Step 1: Diagnose the failure of current approaches with precision. Do not simply assert that unmet need exists. Explain specifically what current approaches do wrong, why they fail your patient population, and what the clinical or biological consequence of that failure is. The more precise your diagnosis of the problem, the more credible your proposed solution.

Step 2: Articulate your scientific hypothesis with rigor. Your hypothesis should name the specific target or mechanism you are pursuing, the foundational biological evidence that supports it (published research, your own preliminary observations, or academic collaborator data), and the specific reason your approach differs from what has been tried before.

Step 3: Connect your pre-seed capital to a specific milestone. Investors need to understand precisely what their capital will generate. “Fund our operations” is not a milestone. “Generate in vitro confirmation of target engagement using our novel allosteric binding model, supporting an SBIR Phase II application and seed-stage conversations” is a milestone. The more specifically you can describe what data will exist that does not exist today, the more confident an investor can be that their check produces a fundable next step.

Step 4: Show what the milestone unlocks. A milestone that does not connect to a next step is a dead end. Explain what your target milestone de-risks, why it is sufficient to support a seed conversation, and what the seed round will then fund. Investors evaluate the full trajectory, not just the next step, so understanding what the Series A bar will eventually require helps you design pre-seed milestones that build toward it deliberately. A founder who can articulate the whole staircase demonstrates exactly the strategic judgment the pre-seed bet is predicated on.

The difference this makes is easiest to see in two openings for the same company.

Weak pre-seed pitch opening:

“We are developing a first-in-class treatment for [disease] using our proprietary AI-powered platform. The market is worth $12 billion and growing. We are seeking $2 million in pre-seed funding to advance our research.”

Strong pre-seed pitch opening:

“Current [disease] therapies address the downstream symptom, inflammation, while the upstream driver, dysregulated [pathway], remains entirely untargeted. We have identified a novel allosteric binding site on [target protein] that, based on published crystallography from the [Academic Lab] group and our own computational modeling, appears to be uniquely druggable. Our pre-seed raise of $1.8 million will fund the in vitro validation of this site and the synthesis of our first three candidate molecules, generating the preclinical package required for an SBIR Phase II application and a seed round with thesis-fit investors in 18 months.”

The second version gives an investor a specific problem, a specific mechanism, a credible evidentiary basis, a precise use of funds, and a clear view of what the raise will produce. It is not more data. It is more precise reasoning, and at pre-seed, reasoning is what you are selling.

What to Put in Your Pre-Seed Biotech Pitch Deck When Data Is Limited

A general biotech pitch deck highlights the value proposition, the science, the market, the team, and the path to commercialization. At pre-seed, when clinical data is unavailable, each of those elements is adapted to the evidence you actually have. The ten-slide structure below is built specifically for a pre-data raise. For the comprehensive, stage-by-stage version, see The Biotech and Life Science Investor Pitch Deck.

Slide 1: The Problem. The patient reality, the clinical failure of current approaches, and the specific unmet need you address. Make it concrete with patient numbers, failure rates, and the limitations of the current standard of care.

Slide 2: Your Scientific Hypothesis. The specific target or mechanism, the foundational biological rationale, and the non-obvious insight that grounds your approach.

Slide 3: Why Your Approach Is Differentiated. The competitive landscape and the specific reason your approach differs from existing attempts. Be honest about what others have tried and why those attempts fell short.

Slide 4: Foundational Evidence. The academic publications, collaborator relationships, preliminary in vitro observations, or computational modeling that provide the biological basis for your hypothesis. Be precise about what this evidence shows and, just as important, what it does not yet show.

Slide 5: IP Status. Patent applications filed or pending, licensed academic IP, or the trade-secret strategy protecting your core innovation. Include the filing date of your provisional and the anticipated conversion timeline.

Slide 6: Regulatory Pathway Overview. A brief, credible summary of your anticipated development path: likely IND requirements, early clinical design, and FDA interaction strategy. Demonstrating regulatory awareness this early is a significant credibility signal.

Slide 7: Target Patient Population and Market. The specific population you are initially targeting and the addressable market. At pre-seed, rigorous patient-level market sizing is more credible than a broad total-addressable-market claim.

Slide 8: Team and Advisors. The most important slide in the deck at this stage. Include specific credentials, relevant publications, and prior experience for every team member, and name your advisory board members with the specific reason each was recruited.

Slide 9: Use of Funds and Milestone. Precisely what your pre-seed capital will generate: specific experiments, specific outputs, specific timelines. End on the milestone and what it enables for the next round.

Slide 10: Non-Dilutive Validation and Traction. Any SBIR or NIH awards, foundation funding, or academic partnerships that externally validate your science. If you have not yet applied for non-dilutive funding, treat this slide as your reminder to start immediately.

Pre-Seed Biotech Fundraising Mistakes That Signal Inexperience to Investors

Experienced investors read certain mistakes as evidence that a founder does not understand the stage. Each one below is avoidable, and each one quietly costs founders rounds.

Pitching Series A investors with a pre-seed profile. A fund that leads large Series A rounds for clinical-stage companies is not the audience for a pre-clinical, hypothesis-stage company. Every misfit pitch burns time, burns relationship capital, and builds a negative first impression that follows you into future rounds.

Over-claiming scientific evidence. Presenting academic publications as clinical validation, or describing a computational model as “proof of concept” without experimental confirmation, is a credibility-destroying error that experienced investors catch immediately. This is exactly what separates the weak pitch opening above from the strong one: the weak version inflates, the strong version states precisely what the evidence shows and what it does not. Be rigorous about the limits of your own evidence. It is the single clearest signal of scientific maturity you can send.

No IP strategy. A hypothesis with no IP protection is a hypothesis anyone can pursue. Investors at every stage look for IP position, and a provisional patent is inexpensive and quick to prepare with an attorney. There is no justification for approaching investors without one.

Solo founder with no team or advisors. At pre-seed, the team is the primary bet, and a solo scientist with no co-founder, no key early hire, and no advisory board signals that the program’s execution risk has not been addressed. Even a part-time co-founder, a committed scientific advisor, or a named hire for a critical role materially reduces that concern.

No non-dilutive funding strategy. Founders who have not explored SBIR, NIH, NSF, or foundation grants before approaching venture investors leave both capital and credibility on the table. Non-dilutive funding keeps your equity intact and signals that your science survived independent peer review. Skipping it entirely tells an investor you have not done the basic work of the stage.

Unclear use of funds. “Fund operations” is not a use of funds. It is an admission that the capital has not been connected to a specific output. Every dollar of pre-seed capital should be traceable to a specific experiment, a specific hire, or a specific regulatory action that produces a fundable milestone.

Treating pre-seed as just a smaller seed round. Pre-seed and seed are different propositions with different bars. Pitch a pre-seed round on team, hypothesis, IP, validation, and milestone, not on diluted, premature claims of traction you cannot back up.

A Practical 12-Month Roadmap for Pre-Seed Biotech Fundraising

The infrastructure above does not assemble itself in the weeks before a raise. Here is how to build it across a year, so that formal outreach happens in the back half, after the credibility signals are already in place.

Q1: Build the Foundation, Hypothesis, IP, and Infrastructure (Months 1 to 3)

The first quarter is about formalizing the scientific and legal infrastructure that every investor conversation will depend on.

• Formalize your scientific hypothesis in writing. Produce a two to three page rationale document: the problem, the biological basis for your target or mechanism, the existing academic evidence, the specific differentiation from current approaches, and your preliminary experimental plan. This document becomes the foundation of every investor conversation and grant application that follows.
• File a provisional patent application. Engage a patent attorney with biotech experience and file a provisional covering your core claims. It establishes your priority date and gives you twelve months to file the full application. Do not approach investors before this is done.
• Identify and apply for your first non-dilutive opportunity. Research SBIR Phase I solicitations at NIH, NSF, and the DoD that fit your program. NIH Phase I generally requires no preliminary data, so apply now, before you have a full preclinical package. In parallel, identify disease-focused foundation grants in your therapeutic area.
• Build your initial target investor list. Research pre-seed and seed-stage biotech investors using portfolio pages, funding trackers, and your own network. Build a list of 30 to 50 investors verified for stage fit and thesis fit. For the targeting and CRM framework, see How to Build an Investor Pipeline for Biotech and Medtech Founders.
• Set up a simple CRM. Even at pre-seed, a basic pipeline tracker keeps every investor relationship organized and every next action visible.

Q2: Build Credibility, Data, Advisors, and Visibility (Months 4 to 6)

The second quarter is about generating the preliminary evidence and external validation that convert a hypothesis into a fundable program.

• Generate your first in vitro validation result. The goal is not a complete preclinical package. It is one clean, well-designed experiment that confirms a foundational aspect of your hypothesis: target engagement, binding affinity, or mechanism of action. That single result is the biological anchor that makes every later conversation more credible.
• Recruit your first two advisory board members. Identify the most credible voices in your disease area and target mechanism, and approach them with a specific ask, not a generic advisory title. Named, engaged advisors transform a founder’s hypothesis into a peer-endorsed program.
• Begin building your founder visibility. Launch or sharpen your presence and start building the visibility that makes you findable before you pitch. Post substantive scientific commentary in your area, ideally a few times a week, and publish at least one long-form piece. A focused LinkedIn strategy is the highest-leverage channel for reaching biotech investors directly.
• Map warm introduction paths. For your top 10 to 15 targets, map every possible warm-introduction route through your academic network, advisors, and connections. Do not begin cold outreach until the warm paths are built or exhausted.

Q3: Begin Investor Conversations, Value-First Outreach (Months 7 to 9)

The third quarter is about initiating the relationships that will either generate your pre-seed round or mature into seed conversations over the following year.

• Begin value-first outreach to your highest-priority investors. Warm, personalized, research-driven outreach framed as peer scientific dialogue, not a pitch. “I have been following your investments in [therapeutic area] and would welcome your perspective on our approach to [mechanism]” outperforms any version of “I would like to share our exciting opportunity.” For the mechanics of outreach that actually gets responses, see Why Biotech Investor Outreach Fails and How to Fix It.
• Attend one well-chosen early-stage event. Disease-specific research conferences and emerging-company tracks at major industry events are the right venues at this stage. Know which investors and advisors you want to meet, and set a specific goal for each conversation.
• Complete and submit your SBIR application. If you applied in Q1, your score should be available now. If you are applying now, submit with a Q4 notification timeline in mind. An SBIR submission, even a pending one, is a credibility signal you can reference in outreach.
• Launch your quarterly investor update. Send the first update to your opted-in contacts, advisors, angels, and warm contacts from events. Frame it as a scientific progress reflection, not a sales pitch.

Q4: Execute the Raise, Parallel Outreach and Pipeline Management (Months 10 to 12)

The fourth quarter converts nine months of infrastructure into a formal fundraising process.

• Finalize your deck and one-pager. Incorporate every piece of evidence generated over the preceding nine months: in vitro data, any SBIR award or submission, advisory board additions, and any preprint or publication.
• Run parallel outreach within a tight window. Simultaneous outreach to your full target list within roughly two weeks creates competitive dynamics and signals organizational confidence. For the full outreach and positioning system, see Capital Raise Marketing for Biotech, Medtech, and Diagnostics.
• Manage pipeline momentum actively. Update your CRM after every interaction, track stage progression in real time, and build specific re-engagement triggers for relationships that stall.
• Close, then immediately plan your seed milestones. On day one after close, begin defining the specific milestones your pre-seed capital will generate and the seed-stage narrative you will build around them. Seed preparation starts the day the pre-seed round closes.

The Pre-Seed Bet Is on You: Make That Case Clearly

Raising pre-seed biotech capital with no clinical data is not about pretending you have proof you do not. It is about understanding that proof is not what this stage funds. The investors who write checks before the science is de-risked are betting on a credible team, a rigorous scientific hypothesis, defensible IP, external validation, and a precise plan to generate the first meaningful data.

They exist specifically to fund that moment, through specialist VCs and company-creation firms, accelerators, domain-expert angels, academic and corporate vehicles, and the non-dilutive lane that lets you produce data without surrendering equity.

In a market concentrating capital in later-stage companies, your preparation matters more, not less. Get the targeting right, build your raise around the five things investors actually evaluate, frame the round as the capital that buys one specific milestone, and make your own credibility visible enough to stand in for the dataset you do not yet have.

That is how you break the catch-22: not by waiting for proof you cannot afford to generate, but by raising the round that lets you generate it.

---

Book a Strategy Call to build and pressure-test your pre-seed raise before you start pitching or Explore My Services to see how founder positioning, investor targeting, and outreach come together for founders raising before they have data.

---

Frequently Asked Questions

---